Bristol-Myers Squibb Company Ce
Bristol-Myers Squibb Company Ce CELG-RI Peers
See (CELG-RI) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CELG-RI | $0.03 | +0.00% | 84.1B | N/A | N/A | +5.25% |
| LLY | $779.53 | +0.00% | 735.7B | 63.37 | $12.25 | +0.72% |
| AZN | $69.88 | +0.00% | 443.1B | 28.81 | $2.48 | +2.21% |
| JNJ | $152.75 | +0.00% | 375.1B | 17.34 | $8.99 | +3.31% |
| ABBV | $185.62 | +0.00% | 335.6B | 81.55 | $2.33 | +3.45% |
| NVO | $69.02 | +0.00% | 309.2B | 19.24 | $3.63 | +2.34% |
| NVS | $121.01 | +0.00% | 243.1B | 19.29 | $6.38 | +3.30% |
| MRK | $79.16 | +0.00% | 205.5B | 11.89 | $6.88 | +4.05% |
| AMGN | $279.21 | +0.00% | 156.2B | 26.46 | $10.98 | +3.34% |
| PFE | $24.24 | +0.00% | 142.4B | 18.14 | $1.38 | +7.03% |
Stock Comparison
CELG-RI vs LLY Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, LLY has a market cap of 735.7B. Regarding current trading prices, CELG-RI is priced at $0.03, while LLY trades at $779.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas LLY's P/E ratio is 63.37. In terms of profitability, CELG-RI's ROE is +0.32%, compared to LLY's ROE of +0.77%. Regarding short-term risk, CELG-RI is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs AZN Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, AZN has a market cap of 443.1B. Regarding current trading prices, CELG-RI is priced at $0.03, while AZN trades at $69.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AZN's P/E ratio is 28.81. In terms of profitability, CELG-RI's ROE is +0.32%, compared to AZN's ROE of +0.19%. Regarding short-term risk, CELG-RI is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs JNJ Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, JNJ has a market cap of 375.1B. Regarding current trading prices, CELG-RI is priced at $0.03, while JNJ trades at $152.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas JNJ's P/E ratio is 17.34. In terms of profitability, CELG-RI's ROE is +0.32%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, CELG-RI is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs ABBV Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, ABBV has a market cap of 335.6B. Regarding current trading prices, CELG-RI is priced at $0.03, while ABBV trades at $185.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ABBV's P/E ratio is 81.55. In terms of profitability, CELG-RI's ROE is +0.32%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, CELG-RI is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs NVO Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, NVO has a market cap of 309.2B. Regarding current trading prices, CELG-RI is priced at $0.03, while NVO trades at $69.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas NVO's P/E ratio is 19.24. In terms of profitability, CELG-RI's ROE is +0.32%, compared to NVO's ROE of +0.81%. Regarding short-term risk, CELG-RI is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs NVS Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, NVS has a market cap of 243.1B. Regarding current trading prices, CELG-RI is priced at $0.03, while NVS trades at $121.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas NVS's P/E ratio is 19.29. In terms of profitability, CELG-RI's ROE is +0.32%, compared to NVS's ROE of +0.31%. Regarding short-term risk, CELG-RI is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs MRK Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, MRK has a market cap of 205.5B. Regarding current trading prices, CELG-RI is priced at $0.03, while MRK trades at $79.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas MRK's P/E ratio is 11.89. In terms of profitability, CELG-RI's ROE is +0.32%, compared to MRK's ROE of +0.38%. Regarding short-term risk, CELG-RI is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs AMGN Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, AMGN has a market cap of 156.2B. Regarding current trading prices, CELG-RI is priced at $0.03, while AMGN trades at $279.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AMGN's P/E ratio is 26.46. In terms of profitability, CELG-RI's ROE is +0.32%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, CELG-RI is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs PFE Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, PFE has a market cap of 142.4B. Regarding current trading prices, CELG-RI is priced at $0.03, while PFE trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas PFE's P/E ratio is 18.14. In terms of profitability, CELG-RI's ROE is +0.32%, compared to PFE's ROE of +0.09%. Regarding short-term risk, CELG-RI is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs GILD Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, GILD has a market cap of 139B. Regarding current trading prices, CELG-RI is priced at $0.03, while GILD trades at $110.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GILD's P/E ratio is 14.44. In terms of profitability, CELG-RI's ROE is +0.32%, compared to GILD's ROE of +0.32%. Regarding short-term risk, CELG-RI is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs SNY Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, SNY has a market cap of 119.5B. Regarding current trading prices, CELG-RI is priced at $0.03, while SNY trades at $48.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SNY's P/E ratio is 16.91. In terms of profitability, CELG-RI's ROE is +0.32%, compared to SNY's ROE of +0.08%. Regarding short-term risk, CELG-RI is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs BMY Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, BMY has a market cap of 96.7B. Regarding current trading prices, CELG-RI is priced at $0.03, while BMY trades at $46.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BMY's P/E ratio is 17.73. In terms of profitability, CELG-RI's ROE is +0.32%, compared to BMY's ROE of +0.32%. Regarding short-term risk, CELG-RI is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs GSK Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, GSK has a market cap of 79.7B. Regarding current trading prices, CELG-RI is priced at $0.03, while GSK trades at $38.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GSK's P/E ratio is 19.09. In terms of profitability, CELG-RI's ROE is +0.32%, compared to GSK's ROE of +0.22%. Regarding short-term risk, CELG-RI is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs HZNP Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CELG-RI is priced at $0.03, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CELG-RI's ROE is +0.32%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CELG-RI is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs BIIB Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, BIIB has a market cap of 19.1B. Regarding current trading prices, CELG-RI is priced at $0.03, while BIIB trades at $125.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BIIB's P/E ratio is 12.85. In terms of profitability, CELG-RI's ROE is +0.32%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, CELG-RI is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs GRFS Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, GRFS has a market cap of 7.5B. Regarding current trading prices, CELG-RI is priced at $0.03, while GRFS trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GRFS's P/E ratio is 33.33. In terms of profitability, CELG-RI's ROE is +0.32%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, CELG-RI is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs OGN Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, OGN has a market cap of 2.6B. Regarding current trading prices, CELG-RI is priced at $0.03, while OGN trades at $9.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas OGN's P/E ratio is 3.49. In terms of profitability, CELG-RI's ROE is +0.32%, compared to OGN's ROE of +1.82%. Regarding short-term risk, CELG-RI is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs CTOR Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, CTOR has a market cap of 371.4M. Regarding current trading prices, CELG-RI is priced at $0.03, while CTOR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -13.66. In terms of profitability, CELG-RI's ROE is +0.32%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, CELG-RI is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs SCLX Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, SCLX has a market cap of 42M. Regarding current trading prices, CELG-RI is priced at $0.03, while SCLX trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCLX's P/E ratio is -0.40. In terms of profitability, CELG-RI's ROE is +0.32%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, CELG-RI is more volatile compared to SCLX. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs SCLXW Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, SCLXW has a market cap of 36.4M. Regarding current trading prices, CELG-RI is priced at $0.03, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCLXW's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is +0.32%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, CELG-RI is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs MIRA Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, MIRA has a market cap of 21M. Regarding current trading prices, CELG-RI is priced at $0.03, while MIRA trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas MIRA's P/E ratio is -2.57. In terms of profitability, CELG-RI's ROE is +0.32%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, CELG-RI is more volatile compared to MIRA. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs SRXH Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, SRXH has a market cap of 7.7M. Regarding current trading prices, CELG-RI is priced at $0.03, while SRXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SRXH's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is +0.32%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, CELG-RI is more volatile compared to SRXH. This indicates potentially higher risk in terms of short-term price fluctuations for CELG-RI.
CELG-RI vs CRXT Comparison
CELG-RI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 84.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.03, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CRXT's P/E ratio is -0.02. In terms of profitability, CELG-RI's ROE is +0.32%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, CELG-RI is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for CELG-RI.